Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.
Cutaneous T-cell Lymphoma|Mycosis Fungoides|Sezary Syndrome
DRUG: Doxycycline monohydrate
Efficacy of Doxycycline in relapsed CTCL, Overall response rate will be determined after five months or a year from initiation of therapy., From baseline to five month or a year depending on response.
Duration of Response, Patients who achieve a Partial Response or Complete Response will be monitored for progression up to one year after initiation of therapy., From baseline to up to one year.
Quality of Life evaluation, Changes in quality of life will be measured throughout the study using questionnaires., Baseline to up to one year.|Pruritus (Itchiness) evaluation, Changes in quality of life will be measured throughout the study using questionnaires., Baseline to up to one year.
The aim of this study is to evaluate the efficacy of doxycycline in relapsed Cutaneous T-cell Lymphomas (CTCL). The primary objective is to determine the overall response rate of doxycycline monotherapy in patients with relapsed CTCL.